Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;28(2):323-329.
doi: 10.1007/s40477-023-00843-y. Epub 2024 Jan 16.

Longitudinal assessment of liver stiffness using ARFI technique does not support increased risk of fibrosis in rheumatoid arthritis patients on methotrexate

Arne Schäfer  1   2 , Magdolna Szilvia Kovacs  3 , Anna Eder  3 , Axel Nigg  3 , Martin Feuchtenberger  4   5
Affiliations

Longitudinal assessment of liver stiffness using ARFI technique does not support increased risk of fibrosis in rheumatoid arthritis patients on methotrexate

Arne Schäfer et al. J Ultrasound. 2025 Jun.

Abstract

Aims: To assess the liver stiffness in patients with rheumatoid arthritis treated with methotrexate monotherapy using non-invasive, ultrasound-based elastography (acoustic radiation force impulse (ARFI) imaging) in a longitudinal approach.

Methods: In total, 23 MTX-naive patients were longitudinally assessed using acoustic radiation force impulse (ARFI) imaging. Baseline assessments were carried out between July 2018 and April 2019, and the follow-up evaluations took place after an average of 2.6 years. The main outcome variable was the mean shear wave velocity as measured by the ARFI method. It was calculated from 10 valid ARFI measurements for each patient. Inferential statistical analyses (within-group comparisons) were performed using t-tests for dependent samples or suitable nonparametric procedures.

Results: The main finding was that observed ARFI shear wave velocities did not increase during the observation period. In fact, this parameter decreased over time from 1.07 m/s (SD = 0.23) at baseline without MTX exposure to 0.97 m/s (SD = 0.16) at follow-up after a mean of 2.6 years (P = 0.013). Moreover, the magnitude of the change in shear wave velocity could not be predicted by indicators of inflammation or disease activity, BMI, age, sex or NSAR intake (corresponding regression analysis: corrected R2 = 0.344; P = 0.296).

Conclusions: No increased risk of liver fibrosis was found in RA patients treated with MTX monotherapy during observation period.

Keywords: ARFI; Arthritis, Rheumatoid; Disease modifying antirheumatic drugs; Fibroscan; Fibrosis, Liver; Methotrexate.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: Dr. Schäfer reports personal fees from Amgen, AstraZeneca, Novo Nordisk Pharma GmbH, outside the submitted work. Dr. Kovacs has nothing to disclose. Dr. Eder has nothing to disclose. Dr. Nigg has nothing to disclose. Dr. Feuchtenberger reports personal fees from AbbVie, personal fees from Novartis, personal fees from Roche, and personal fees from UCB outside of the submitted work. All authors disclose financial or non-financial interests that are directly or indirectly related to the work submitted for publication. Ethical approval: The study was approved by the Ethics Committee of the University of Würzburg, Würzburg, Germany, on 12 July 2018 (2/18-me). Informed consent: All patients provided written informed consent for blood analysis, study participation and publication of data.

Similar articles

See all similar articles

References

    1. Skinner MD, Schwartz RS (1974) Immunosuppressive therapy of immunoinflammatory diseases. Rheumatology 5:1–48 - PubMed
    1. Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, De Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, Den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, Mcinnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, Van Der Helm-Van MA, Van Duuren E, Vliet Vlieland TPM, Westhovens R, Van Der Heijde D (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3–18. 10.1136/ard-2022-223356 - PubMed
    1. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millan I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA (2021) 2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 73:924–939. 10.1002/acr.24596 - PMC - PubMed
    1. Weinstein GD, Cox JW, Suringa DW, Millard MM, Kalser M, Frost P (1970) Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis. Arch Dermatol 102:613–618 - PubMed
    1. Roenigk HH Jr, Bergfeld WF, St Jacques R, Owens FJ, Hawk WA (1971) Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch Dermatol 103:250–261 - PubMed

LinkOut - more resources